Dapasmart: Advanced Relief for Gastrointestinal Spasms
Dapasmart
| Product dosage: 10mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 14 | $5.07 | $71.00 (0%) | 🛒 Add to cart |
| 28 | $4.25 | $142.00 $119.00 (16%) | 🛒 Add to cart |
| 56 | $3.89 | $284.00 $218.00 (23%) | 🛒 Add to cart |
| 84 | $3.74 | $426.00 $314.00 (26%) | 🛒 Add to cart |
| 112 | $3.52 | $568.00 $394.00 (31%) | 🛒 Add to cart |
| 168 | $3.42
Best per pill | $852.00 $575.00 (33%) | 🛒 Add to cart |
| Product dosage: 5mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 14 | $4.79 | $67.00 (0%) | 🛒 Add to cart |
| 28 | $3.89 | $134.00 $109.00 (19%) | 🛒 Add to cart |
| 56 | $3.57 | $268.00 $200.00 (25%) | 🛒 Add to cart |
| 84 | $3.50 | $402.00 $294.00 (27%) | 🛒 Add to cart |
| 112 | $3.39 | $536.00 $380.00 (29%) | 🛒 Add to cart |
| 168 | $3.23
Best per pill | $804.00 $542.00 (33%) | 🛒 Add to cart |
Synonyms | |||
Dapasmart represents a significant advancement in the management of functional gastrointestinal disorders characterized by painful smooth muscle spasms. This prescription medication, with its targeted antispasmodic action, is specifically formulated to alleviate abdominal pain, cramping, and bloating associated with conditions like Irritable Bowel Syndrome (IBS). Its unique formulation ensures rapid onset of action with a favorable side effect profile, making it a cornerstone in gastroenterological therapeutic regimens. By directly targeting the hyperactive smooth muscle of the gastrointestinal tract, Dapasmart restores normal motility and provides predictable, sustained relief, allowing patients to regain control over their daily lives.
Features
- Active Pharmaceutical Ingredient: Mebeverine Hydrochloride 135 mg
- Pharmaceutical Form: Film-coated, extended-release tablet
- Mechanism of Action: Direct smooth muscle relaxant with minimal anticholinergic effects
- Pharmacokinetic Profile: Designed for sustained release over 12 hours
- Excipients: Lactose monohydrate, microcrystalline cellulose, hypromellose, colloidal silicon dioxide, magnesium stearate
- Bioavailability: Approximately 30-40% under fasting conditions
- Protein Binding: Low (<50%)
- Metabolism: Extensive first-pass metabolism primarily via esterase hydrolysis
- Elimination Half-life: 1.5 - 3.5 hours for active metabolites
- Primary Excretion Route: Renal (>90% as metabolites)
Benefits
- Provides rapid and effective relief from acute episodes of gastrointestinal spasms and associated pain.
- Normalizes intestinal motility without causing paralytic ileus or significant alterations in gut flora.
- Minimizes systemic anticholinergic side effects such as dry mouth, blurred vision, or urinary retention commonly associated with older antispasmodics.
- The extended-release formulation ensures consistent therapeutic plasma levels, reducing the frequency of dosing and improving patient compliance.
- Allows for long-term management of chronic functional bowel disorders with a well-established safety profile.
- Helps restore quality of life by reducing the frequency and severity of symptomatic episodes, enabling normal daily and social activities.
Common use
Dapasmart is primarily indicated for the symptomatic treatment of Irritable Bowel Syndrome (IBS), particularly where abdominal pain and spasm are predominant features. It is extensively used in the management of functional gastrointestinal disorders including spastic colon, irritable colon, and mucous colitis. Clinicians also prescribe it for gastrointestinal spasm secondary to organic diseases, such as diverticulitis or cholelithiasis, when symptomatic relief is required. Its use is common in patients who have not responded adequately to dietary modifications, fiber supplements, or lifestyle changes alone. It is considered a first-line pharmacological agent in many international guidelines for IBS management.
Dosage and direction
The standard adult dosage for Dapasmart is one 135 mg tablet taken three times daily, preferably 20 minutes before meals (breakfast, lunch, and dinner). The tablets must be swallowed whole with a glass of water and should not be chewed, crushed, or broken, as this will compromise the extended-release mechanism. The duration of treatment is determined by the prescribing physician based on symptomatic response; however, a therapeutic trial of at least two weeks is typically recommended to assess efficacy. For elderly patients or those with mild to moderate hepatic impairment, no initial dosage adjustment is necessary, but close monitoring is advised. The safety and efficacy in children under 18 years of age have not been established.
Precautions
Patients should be advised that Dapasmart is intended for the relief of symptoms and does not treat the underlying cause of gastrointestinal disorders. A thorough diagnostic workup should be completed to rule out organic pathology before initiating long-term therapy. Use with caution in patients with a known hypersensitivity to any of the inactive ingredients, particularly lactose. While the risk is low, patients should be monitored for signs of paralytic ileus, especially in those with predisposing conditions. It is not recommended for use during pregnancy unless clearly necessary, as limited human data is available. Breastfeeding mothers should consult their physician, as it is unknown whether mebeverine is excreted in human milk.
Contraindications
Dapasmart is contraindicated in patients with a known hypersensitivity to mebeverine hydrochloride or any of the excipients listed in the formulation. Its use is absolutely contraindicated in patients with paralytic ileus, severe hepatic impairment (Child-Pugh Class C), or intestinal obstruction. It should not be administered to patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency, or glucose-galactose malabsorption due to the lactose content. Concomitant use with other potent antispasmodic agents is not recommended.
Possible side effect
The majority of patients tolerate Dapasmart well. The following adverse reactions have been reported, typically mild and transient in nature:
- Common (≥1/100 to <1/10): Headache, mild dizziness, nausea.
- Uncommon (≥1/1,000 to <1/100): Heartburn, constipation, diarrhea, skin rash, urticaria.
- Rare (≥1/10,000 to <1/1,000): Angioedema, anaphylactic reactions. Patients should be instructed to report any persistent or severe side effects to their healthcare provider immediately. Discontinuation of therapy typically leads to a rapid resolution of these adverse effects.
Drug interaction
Formal drug interaction studies are limited. However, due to its metabolic pathway, clinically significant interactions with drugs metabolized by the CYP450 system are not expected. Theoretical interactions exist with other drugs that affect gastrointestinal motility (e.g., metoclopramide, domperidone, opioids, anticholinergics), which may antagonize or potentiate effects. Caution is advised when administering with other esterase-metabolized drugs. Always inform your physician of all prescription, over-the-counter, and herbal products you are taking.
Missed dose
If a dose is missed, it should be taken as soon as remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped. Patients should never take a double dose to make up for a forgotten one. Maintaining a regular dosing schedule is important for optimal symptom control.
Overdose
Symptoms of overdose would be primarily related to excessive pharmacological effect and may include marked dizziness, severe nausea, and cardiac arrhythmias. There is no specific antidote for mebeverine overdose. Treatment should be supportive and symptomatic, including gastric lavage if ingestion was recent. Monitoring of vital signs and cardiac function is recommended. Hemodialysis is unlikely to be beneficial due to the high protein binding and extensive metabolism of the drug.
Storage
Store Dapasmart tablets in the original blister pack at room temperature (15°C - 25°C or 59°F - 77°F). Protect from light and moisture. Keep the medication out of sight and reach of children and pets. Do not use after the expiration date printed on the packaging. Do not dispose of medication via wastewater or household waste; return any unused or expired product to a pharmacy for proper disposal.
Disclaimer
This information is intended for educational purposes and does not constitute medical advice. It is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any new treatment. Never disregard professional medical advice or delay in seeking it because of something you have read in this product description.
Reviews
“After years of struggling with IBS-C and trying numerous treatments, Dapasmart has been a game-changer. The abdominal pain and cramping have reduced significantly within the first week of use. I appreciate that it doesn’t cause the drowsiness or dry mouth I experienced with other antispasmodics.” – Eleanor R., Patient
“From a clinical perspective, Dapasmart is a reliable and effective first-line option for our IBS patients. Its targeted action and favorable side effect profile make it suitable for long-term management. Patient compliance is high due to the tid dosing schedule that aligns with meals.” – Dr. Benjamin Clarke, Gastroenterologist
“The extended-release formulation provides consistent symptom control throughout the day, which has allowed me to return to work full-time without the constant worry of a painful flare-up. It has genuinely restored a sense of normalcy to my life.” – Marcus T., Patient
“In our gastroenterology practice, we find Dapasmart to be particularly effective for patients with pain-predominant IBS. It effectively reduces colonic spasm without completely halting motility, which is a crucial balance to strike. It’s a well-tolerated and predictable agent.” – Dr. Susan Li, Consulting Gastroenterologist